Neptunus Pharmaceuticals Inc.   Report issue

For profit Phase 2
Founded: Shenzhen China (1989)
Status: No NME R&D (1989)

Organization Overview

First Clinical Trial
2013
NCT01780129
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

polydotin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Shock (Phase 2)

Shock, Hemorrhagic (Phase 2)

Shock, Septic (Phase 2)

Shock, Traumatic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1